The Hyderabad-based company has received the approval from the US Food and Drug Administration (USFDA) to market its product which is a generic equivalent of Eli Lilly and Company#39;s Straterra, Dr Reddy#39;s Laboratories said in a statement.Dr Reddy#39;s Labs announces generic version of Straterra in US market
The Hyderabad-based company has received the approval from the US Food and Drug Administration (USFDA) to market its product which is a generic equivalent of Eli Lilly and Company#39;s Straterra, Dr Reddy#39;s Laboratories said in a statement.
Subscribe to:
Post Comments (Atom)
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
-
In July, HCL Technologies had announced a Rs 4,000 crore buyback programme for FY19 at a price of Rs 1,100 per equity share.
No comments:
Post a Comment